Dr. Jordi Monés to participate at the 14th Euretina Congress in London

Dr. Jordi Monés, MD, PhD, the Medical Director of the Institut de la Màcula is to attend the 14th Euretina Congress, to be held in London on 11‑14 September and organised by the European Society of Retina Specialists (EURETINA).

On Friday 12 September, Dr. Monés will chair the symposium: “Ranibizumab: Expanding Horizons in RVO Management”, organised by Novartis, on treatment of retinal venous occlusion (RVO). He will then give a lecture titled: What does early neovascular AMD look like? at the session on AMD.

On Saturday, the Institut team - Dr. H. Almuhtaseb, Dr. J. Badal, Dr. M. Biarnés and Dr. Monés himself- will present the study “Performance characteristics of multicolour versus blue light and infrared imaging in the identification of reticular pseudodrusen”.

That same day, Dr. Monés together with  M. Larsen, F. Boscia, H. Gerding, I. Pearce, S. Priglinger, R. Tadayoni, M. Gekkieva and A. Lotery, will speak at a session on: “Individually dosed ranibizumab, alone or combined with laser, versus laser alone in branch retinal vein occlusion patients with visual impairment due to macular edema- 6 month results of the BRIGHTER study”.

At the session on vascular disease and diabetic retinopathy, Dr. Monés will take part at a presentation on “Efficacy and safety of ranibizumab 0.5 mg in patients with visual impairment due to macular edema secondary to central retinal vein occlusion- design and baseline characteristics of the CRYSTAL study” with P. Hykin, H. Gerding, F. Boscia, R. Tadayoni,S. Priglinger, I. Pearce, W. Stubbings,M. Gekkieva and A. Cole.

On Sunday 14 September, Dr. Monés will speak at the Spanish Vitreoretinal Society (SERV) symposium on pathological myopia to explain “Anti-VEGF therapy for choroidal neovascular membranes”. During his stay in London, Dr. Monés’s schedule also includes attendance on a variety of Advisory Boards, such as Roche, Teva, Eyela and Lampalizumab.